logo

ABUS

Arbutus Biopharma·NASDAQ
--
--(--)
--
--(--)
5.00 / 10
Netural

Fund-flow analysis is encouraging (7.68/10), with robust inflows across most size brackets—block, small, large, and extra-large—suggesting underlying buying interest. However, medium-sized flows lean negative, hinting at selective profit-taking. Analyst sentiment is overwhelmingly bullish with a Strong Buy rating from one institution, yet the small coverage base limits conviction. Together, the data point to a cautiously optimistic but still speculative investment climate.

FundamentalSentiment(5)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-11-14
InstitutionChardan Capital
Times predicted3
Historical Win Rate33.3%
What is the market sentiment for ABUS?
  • ABUS holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.00/10 (Netural).